# A matching‐adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR‐2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor

**Authors:** Georg Heß, Toby A. Eyre, Min‐Hua Jen, Jiewen Zhang, Benjamin Goebel, Sarang Abhyankar, Martin Dreyling

PMC · DOI: 10.1111/bjh.70237 · British Journal of Haematology · 2025-11-17

## Full-text entities

- **Genes:** BTK (Bruton tyrosine kinase) [NCBI Gene 695] {aka AGMX1, AT, ATK, BPK, IGHD3, IMD1}
- **Diseases:** mantle cell lymphoma (MESH:D020522)
- **Chemicals:** pirtobrutinib (MESH:C000723100), BRUIN (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12819100/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12819100/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12819100/full.md

---
Source: https://tomesphere.com/paper/PMC12819100